Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
SciBase Holding AB is a medical technology company specializing in advanced diagnostic solutions for skin conditions. The company develops, manufactures, and commercializes Nevisense, a point-of-care platform that combines augmented intelligence and electrical impedance spectroscopy (EIS) to support clinicians in assessing skin cancer risk and skin barrier function. Nevisense is designed to improve diagnostic accuracy in routine dermatology workflows, particularly for the early detection of melanoma and other skin disorders, and is used by dermatologists and skin cancer clinics in both Europe and the United States. SciBase’s technology supports proactive skin health management by providing objective, non-invasive measurements that complement visual examination and dermoscopy. Headquartered in Stockholm, Sweden, SciBase today operates in multiple international markets, with a focus on dermatology practices where improved risk assessment and early detection can enhance clinical decision-making and patient management.
kr 2.88
+kr 0.12 (+4.17%)
EOD Jun 25, 2026 · Twelve Data
The business is unprofitable at the operating level (-210.51% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 36.2% YoY with margins expanding 14.9pp.
ROIC dropped from -116.67% to -190.85%, capital efficiency is deteriorating. Negative free cash flow of -kr 85M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 46M
▲ +36.2% YoY
Net Income (TTM)
-kr 95M
▼ -42.4% YoY
Op. Margin
-198.96%
▲ +14.9pp YoY
ROIC
-190.85%
▼ -74.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 85M
▼ -46.7% YoY
Op. Cash Flow (TTM)
-kr 19M
▼ -47.4% YoY
Net Debt
kr 425K
Cash & Equiv.
kr 23M
3Y CAGR: +31.3%
Continue Research
SciBase Holding AB (SCIB.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, SciBase Holding AB scores 40/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
SciBase Holding AB scores 40 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -199.0% operating margin and a -190.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh SCIB.XSTO's valuation and scores 40/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.